Stonepine Capital’s managing member is Timothy Lynch. The life science industry is the primary focus of the investment management firm. Amryt Pharma Plc is the firm’s largest stock position, accounting for 31.79 percent of its total holdings. Timothy Lynch went to Harvard Business School and Colgate University. Healthcare equities make up nearly 97 percent of Lynch’s Q3 portfolio. Stonepine Capital has a portfolio worth $219.76 million and assets under management worth $246.86 million as of Q3 2021.
Here is Insider Monkey’s list of top 10 healthcare stock picks of Timothy P. Lynch. On November 15, Gamida Cell Ltd. reported Q3 earnings, with EPS of -$0.33, beating estimates by $0.15. The firm specializes in sophisticated cell therapy to treat blood disorders and cancers. On November 10, Affimed N.V. released its third-quarter earnings. The $9.94 million in revenue was down 20.13 percent from the previous quarter, but it was $1.34 million higher than expectations. Apollo Endosurgery, Inc. is worth $8.26 million to Stonepine Capital, accounting for 3.76 percent of the firm’s Q3 13F portfolio. The business creates less intrusive medical gadgets to address a number of gastrointestinal disorders. Strongbridge Biopharma PLC is a biopharmaceutical business that develops therapies for neuromuscular and endocrine diseases. 11 hedge funds were positive on the firm in the third quarter of 2021, with a total holding value of $29.8 million. Catalyst Biosciences, Inc. has announced that the clinical development of its main product, MarzAA, will be halted. Catalyst Biomarkers is the subject of a $10.83 million investment by Stonepine Capital, which accounts for 4.92 percent of the firm’s total holdings. For more details, click Top 10 Healthcare Stock Picks Of Timothy P. Lynch.